Screening premorbid metabolic syndrome in community pharmacies: a cross-sectional descriptive study

BMC Public Health

Marian A March²  Pere Travé¹  Cristina Toro¹  Maria Angeles Via-Sosa² 

[1] Faculty of Pharmacy, University of Barcelona, Catalonia, Spain;Unit of Practice Pharmacy, Unidad de Prácticas Tuteladas, Faculty of Pharmacy, University of Barcelone, Catalonia, Spain

关键词: Diabetes mellitus;    Cardiovascular disease;    Cardiovascular risk;    Metabolic syndrome;    Screening;    Community pharmacy;   

Others  :  1130445
DOI  :  10.1186/1471-2458-14-487

 received in 2014-01-29, accepted in 2014-05-06,  发布年份 2014

【 摘 要 】

Background

Premorbid metabolic syndrome (pre-MetS) is a cluster of cardiometabolic risk factors characterised by central obesity, elevated fasting glucose, atherogenic dyslipidaemia and hypertension without established cardiovascular disease or diabetes. Community pharmacies are in an excellent position to develop screening programmes because of their direct contact with the population.

The main aim of the study was to determine the prevalence of pre-MetS in people who visited community pharmacies for measurement of any of its five risk factors to detect the presence of other risk factors. The secondary aims were to study the presence of other cardiovascular risk factors and determine patients’ cardiovascular risk.

Methods

Cross-sectional, descriptive, multicentre study. Patients meeting selection criteria aged between 18 and 65 years who visited participating community pharmacies to check any of five pre-MetS diagnostic factors were included.The study involved 23 community pharmacies in Catalonia (Spain). Detection criteria for pre-MetS were based on the WHO proposal following IDF and AHA/NHBI consensus. Cardiovascular risk (CVR) was calculated by Regicor and Score methods. Other variables studied were smoking habit, physical activity, body mass index (BMI), and pharmacological treatment of dyslipidemia and hypertension. The data were collected and analysed with the SPSS programme. Comparisons of variables were carried out using the Student’s T-test, Chi-Squared test or ANOVA test. Level of significance was 5% (0.05).

Results

The overall prevalence of pre-MetS was 21.9% [95% CI 18.7-25.2]. It was more prevalent in men, 25.5% [95% CI 22.1-28.9], than in women, 18.6% [95% CI 15.5-21.7], and distribution increased with age. The most common risk factors were high blood pressure and abdominal obesity. About 70% of people with pre-MetS were sedentary and over 85% had a BMI ≥25 Kg/m². Some 22.4% had two metabolic criteria and 27.2% of patients with pre-MetS had no previous diagnosis.

Conclusions

The prevalence of pre-MetS in our study (21.9%) was similar to that found in other studies carried out in Primary Care in Spain. The results of this study confirm emergent cardiometabolic risk factors such as hypertension, obesity and physical inactivity.

Our study highlights the strategic role of the community pharmacy in the detection of pre-MetS in the apparently healthy population.

【 授权许可】

   
2014 Via-Sosa et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Rosenzweig JL, Ferrannini E, Grundy SM, Haffner SM, Heine RJ, Horton ES, Kawamori R: Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008, 93(10):3671-3689.
• [2]Hivert MF, Grant RW, Shrader P, Meigs JB: Identifying primare care patients at risk for future diabetes and cardiovascular disease using electronic health records. BMC Health Serv Res 2009, 9:170. BioMed Central Full Text
• [3]Conthe P, Lobos JM: Definition and current situation of cardiometabolic risk. Rev Clin Esp 2008, 208(2):63-65.
• [4]Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr, International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention: National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120(16):1640-1645.
• [5]Ogbera AO: Prevalence and gender distribution of the metabolic syndrome. Diabetol Metab Syndr 2010, 2:1. BioMed Central Full Text
• [6]Cabré JJ, Martín F, Costa B, Piñol JL, Llor JL, Ortega Y, Basora J, Baldrich M, Solà R, Daniel J, Hernández JM, Saumell J, Bladé J, Sagarra R, Basora T, Montañés D, Frigola JL, Donado-Mazarrón A, García-Vidal MT, Sánchez-Oro I, de Magriñà JM, Urbaneja A, Barrio F, Vizcaíno J, Sabaté JM, Pascual I, Revuelta V: Metabolic syndrome as a cardiovascular disease risk factor: patients evaluated in primary care. BMC Public Health 2008, 8:251. BioMed Central Full Text
• [7]Simmons RK, Alberti KG, Gale EA, Colagiuri S, Tuomilehto J, Qiao Q, Ramachandran A, Tajima N, Brajkovich Mirchov I, Ben-Nakhi A, Reaven G, Hama Sambo B, Mendis S, Roglic G: The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia 2010, 53(4):600-605.
• [8]Santos AA, Severo M, Barros H: Incidence and risk factors for the metabolic syndrome in an urban South European population. Prev Med 2010, 50:99-105.
• [9]Bo S, Ciccone G, Pearce N, Merletti F, Gentile L, Cassader M, Pagano G: Prevalence of undiagnosed metabolic syndrome in a population of adult asymptomatic subjects. Diabetes Res Clin Pract 2007, 75:362-365.
• [10]Olenak JL, Calpin M: Establishing a cardiovascular health and wellness program in a community pharmacy: screening for metabolic syndrome. J Am Pharm Assoc 2010, 50(1):32-36.
• [11]Guía de actuación en Atención Primaria: Riesgo Cardiovascular. Available at: http://www.regicor.org/media/upload/pdf/guia_rcv_baleares_editora_31_2_1.pdf webcite. Last accessed: Jan 2011
• [12]Sociedad Española para el Estudio de la Obesidad (SEEDO): Consenso SEEDO 2000 para la evaluación del sobrepeso y la obesidad y el establecimiento de criterios de intervención terapéutica. Med Clin 2000, 115(15):587-597.
• [13]Baena-Díez JM, del Val Garcia JL, Héctor-Salas L, Sánchez-Pérez R, Altes-Vaques E, Deixens-Martínez B, Amatller-Corominas M, Katia-Núñez D: Comparison of the SCORE and REGICOR models for calculating cardiovascular risk in cardiovascular disease-free individuals at a healthcare center in Barcelona, Spain. Rev Esp Salud Publica 2005, 79(4):453-464.
• [14]Marrugat J, D’Agostino R, Sullivan L, Elosua R, Wilson P, Ordovas J, Solanas P, Cordón F, Ramos R, Sala J, Masiá R, Kannel WB: An adaptation of the Framingham coronary risk function to southern Europe Mediterranean areas. J Epidemiol Community Health 2003, 57:634-638.
• [15]Marrugat J, Subirana I, Comín E, Cabezas C, Vila J, Elosua R, Byung-Ho N, Ramos R, Sala J, Solanas P, Cordón F, Gené-Badia J, D’Agostino RB: Validity of an adaptation of the Framingham cardiovascular risk function: the VERIFICA Study. J Epidemiol Community Health 2007, 61:40-47.
• [16]Fernández-Bergés D, Cabrera de León A, Sanz H, Elosua R, Guembe MJ, Alzamora M, Vega-Alonso T, Félix-Redondo FJ, Ortiz-Marrón H, Rigo F, Lama C, Gavrila D, Segura-Fragoso A, Lozano L, Marrugat J: Metabolic syndrome in Spain: prevalence and coronary risk associated with harmonized definition and WHO proposal. DARIOS study. Rev Esp Cardiol 2012, 65(3):241-248.
• [17]Fernández-Bergés D, Félix-Redondo FJ, Lozano L, Pérez-Castán JF, Sanz H, Cabrera de León A, Hidalgo AB, Morcillo Y, Tejero V, Alvarez-Palacios P: Prevalence of metabolic syndrome estimated with the new World Health Organization recommendations. The HERMEX study. Gac Sanit 2011, 25(6):519-524.
• [18]Lejsková M, Alušík S, Valenta Z, Adámková S, Piťha J: Natural postmenopause is associated with an increase in combined cardiovascular risk factors. Physiol Res 2012, 61(6):587-596.
• [19]Dasgupta S, Salman M, Lokesh S, Xaviour D, Saheb SY, Prasad BV, Sarkar B: Menopause versus aging: the predictor of obesity and metabolic aberrations among menopausal women of Karnataka, South India. J Midlife Health 2012, 3(1):24-30.
• [20]Vinluan CM, Zreikat HH, Levy JR, Cheang KI: Comparison of different metabolic syndrome definitions and risks of incident cardiovascular events in the elderly. Metabolism 2012, 61(3):302-309.
• [21]Gavrila D, Salmerón D, Egea-Caparrós JM, Huerta JM, Pérez-Martínez A, Navarro C, Tormo MJ: Prevalence of metabolic syndrome in Murcia Region, a southern European Mediterranean area with low cardiovascular risk and high obesity. BMC Public Health 2011, 11:562. BioMed Central Full Text
• [22]Hu G, Lindström J, Valle TT, Eriksson JG, Jousilahti P, Silventoinen K, Qiao Q, Tuomilehto J: Physical activity, body mass index, and risk of type 2 diabetes in patients with normal or impaired glucose regulation. Arch Intern Med 2004, 164:892-896.
• [23]Gray LJ, Khunti K, Williams S, Goldby S, Troughton J, Yates T, Gray A, Davies MJ, Let’s Prevent Collaborators: Let’s prevent diabetes: study protocol for a cluster randomised controlled trial of an educational intervention in a multi-ethnic UK population with screen detected impaired glucose regulation. Cardiovasc Diabetol 2012, 11:56. BioMed Central Full Text
• [24]Llop JC, Hernández S, Bítria J, Josa A, Crespo JM, Bejarano F, Llor C: Lifestyles of subjects who take drugs for two or more cardiovascular risk factors. TAR-RISC Study. Aten Primaria 2011, 43(5):229-235.
• [25]Edwardson CL, Gorely T, Davies MJ, Gray LJ, Khunti K, Wilmot EG, Yates T, Biddle SJ: Association of sedentary behaviour with metabolic syndrome: a meta-analysis. PLoS One 2012, 7(4):e34916.
• [26]Dagogo-Jack S, Egbuonu N, Edeoga C: Principles and practice of nonpharmacological interventions to reduce cardiometabolic risk. Med Princ Pract 2010, 19(3):167-175.
• [27]Katoue MG, Awad AI, Kombian SB: Role of community pharmacists in the prevention and management of the metabolic syndrome in Kuwait. Int J Clin Pharm 2013, 35:57-64.
• [28]Rin EO, Shin A, Kim J, Ha S, Sung J: Leisure-time physical activity is associated with a reduced risk for metabolic syndrome. Ann Epidemiol 2009, 19:784-792.
• [29]Joseph LJ, Prigeon RL, Blumenthal JB, Ryan AS, Goldberg AP: Weight loss and low-Intensity exercise for the treatment of metabolic syndrome in obese postmenopausal women. J Gerontol A Biol Sci Med Sci 2011, 66(9):1022-1029.
• [30]González Calvo G, Hernández Sánchez S, Pozo Rosado P, García López D: Positive effects of physical exercise on reducing the relationship between subcutaneous abdominal fat and morbility risk. Nutr Hosp 2011, 26(4):685-691.
• [31]Golbidi S, Mesdaghinia A, Laher I: Exercise in the metabolic syndrome. Oxid Med Cell Longev 2012, 2012:349710.
• [32]Sjöling M, Lundberg K, Englund E, Westman A, Jong MC: Effectiveness of motivational interviewing and physical activity on prescription on leisure exercise time in subjects suffering from mild to moderate hypertension. BMC Res Notes 2011, 4:352. BioMed Central Full Text
• [33]Awad A, Waheedi M: Community pharmacists role in obesity treatment in Kuwait: a cross-sectional study. BMC Public Health 2012, 12:863. BioMed Central Full Text
• [34]Huber CA, Mohler-Kuo M, Zellweger U, Zoller M, Rosemann T, Senn O: Obesity management and continuing medical education in primary care: results of a Swiss survey. BMC Fam Pract 2011, 12:140. BioMed Central Full Text
• [35]Mecca MS, Moreto F, Burini FH, Dalanesi RC, McLellan KC, Burini RC: Ten-week lifestyle changing program reduces several indicators for metabolic syndrome in overweight adults. Diabetol Metab Syndr 2012, 4(1):1. BioMed Central Full Text
• [36]Wubben DP, Vivian EM: Effects of pharmacist outpatient interventions on adults with diabetes mellitus: a systematic review. Pharmacotherapy 2008, 28(4):421-436.
• [37]Dent LA, Harris KL, Noonan CW: Randomized trial assessing the effectiveness of a pharmacist-delivered program for smoking cessation. Ann Pharmacother 2009, 43(2):194-201.
• [38]Robinson JD, Segal R, Lopez LM, Doty RE: Impact of a pharmaceutical care intervention on blood pressure control in a chain pharmacy practice. Ann Pharmacother 2010, 44(1):88-96.
• [39]Machado M, Bajcar J, Guzzo GC, Einarson TR: Sensivity of patient outcomes to pharmacist interventions. Part II: Systematic review and meta-analysis in hypertension management. Ann Pharmacother 2007, 41(11):1770-1781.
• [40]Machado M, Bajcar J, Guzzo GC, Einarson TR: Sensivity of patient outcomes to pharmacist interventions. Part III: Systematic review and meta-analysis in hyperlipidemia management. Ann Pharmacother 2008, 42(9):1195-1207.
• [41]Lee CM, Huxley RR, Wildman RP, Woodward M: Indices of abdominal obesity are better discriminators of cardiovascular risk factors than BMI: a meta-analysis. J Clin Epidemiol 2008, 61(7):646-653.
• [42]Aye M, Sazali M: Waist circumference and BMI cut-off points to predict risk factors for metabolic syndrome among outpatients in a district hospital. Singapore Med J 2012, 53(8):545-550.